In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1125-1131

  Espada, R ^a   Valdespina, S ^a   Dea, M A ^a   Molero, G ^a   Ballesteros, M P ^a   Bolas F ^a   Torrado, J J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Aggregation state; Candidiasis; Therapeutic index; Toxicity

Indexed keywords

ALBUMIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANDIDA ALBICANS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; FUNGAL STRAIN; IMMUNOCOMPETENCE; IN VIVO STUDY; INVASIVE CANDIDIASIS; KIDNEY; LD 50; LETHAL DOSE; MICROENCAPSULATION; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; SINGLE DRUG DOSE; SPLEEN;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAT; KIDNEY; LIVER; MICE; MICE, INBRED ICR; SPLEEN; TISSUE DISTRIBUTION;

EID: 42149150384     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn048     Document Type: Article

References (39)

1. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30; 662-78.
2. Bates DW, Su L, Yu DT et al.Correlates of acute ranal failure in patients receiving parenteral amphotericin B. Kidney Int 2001; 60: 1452-9.
3. Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing ragimens of liposomol amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 1096-102.
4. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996; 9: 512-31.
5. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999; 1: 213-83.
6. Andes D, Safdar N, Marchillo K et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006; 50: 674-84.
7. Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Design 2002; 8: 441-54.
8. Brime B, Moreno MA, Frutos G et al. Amphotericin B in oil-water lecithin-based microemulsions: Formulation and toxicity evaluation. J Pharm Sci 2002; 91: 1178-85.
9. Zarif L. Drug delivery by lipid cochleates. Methods Enzymol 2005; 391: 314-29.
10. Charvalos E, Tzatzarakis MN, Van Bambeke F et al. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J Antimicrob Chemother 2006; 57: 236-44.
11. Sánchez-Brunete JA, Dea MA, Rama S et al. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J Drug Target 2005; 13: 225-33.
12. Kayser O, Olbrich C, Yardley V et al. Formulation of amphotericin B as nanosuspensions for oral administration. Int J Pharm 2003; 254: 73-5.
13. Espuelas MS, Legrand P, Campanero MA et al. Polymeric carriers of amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother 2003; 52: 419-27.
14. Gaboriau F, Cheron M, Leroy L et al. Physicochemical properties of the heat-induced superaggregates of amphotericin B.Biophys Chem 1997; 66: 1-12.
15. Saka Y, Mita T. Interaction of amphotericin B with cholesterol in monolayers, acqueous solutions, and phospholipid bilayers. J Biochem 1998; 123: 798-805.
16. Tancrède P, Barwicz J, Jutras S et al. The effect of surfactants on the aggregation state of amphotericin B. Biochim Biophys Acta 1990; 1030: 289-95.
17. Adams ML, Andes DR, Kwon GS. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal-activity. Biomacromolecules 2003; 4: 750-7.
18. Vakil R, Kwon GS. PEG-phospholipid micelles for the delivery of amphotericin B. J Control Release 2005; 101: 386-8.
19. Sanchez-Brunete JA, Dea MA, Roma S et al. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J Drug Target 2004; 12: 453-60.
20. Barlett K, Yau E, Hartsel SC et al. Effect of heat-treated amphotericin B on renal and fungal cytotoxicity. Antimicrob Agents Cbemother 2004; 48: 333-6.
21. van Etten EW, van Vianen W, Roovers P et al. Mild heating of amphoterioin B-deoxycholate: Effects on ultrastructure, in vitro activity and toxioty, and therapeutic efficacy in severe-candidiasis in leukopenic mice. Antimicrob Agents Chemother 2000; 44: 1598-603.
22. Gaboriau F, Cheron M, Petit C et al. Heat-induced superaggregation of amphotericin B reduces its in vitro toxidty: A now way to improve its therapeutic index. Antimicrob Agents Chemother 1997; 41: 2345-51.
23. Petit C, Cheron M, Joly V et al. In vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B (Fungizone) obtained by mild heating. J Antimicrob Chemother 1998; 42: 779-85.
24. Petit C, Yardley V, Gaboriau F et al. Activity of a head-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrob Agents Chemother 1999; 43: 390-2.
25. Sánchez-Brunete JA, Dea MA, Rama S et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004; 48: 3246-52.
26. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics, 3rd ed. New Jersey: Prentice Hall, 1993.
27. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylaseby complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179-82.
28. Brime B, Molero G, Frutos P et al. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans. Eur J Pharm Sci 2004; 22: 451-8.
29. Papadimitriou JM, Ashman RB. The pathogenesis of acute systemic candidiasis in a susceptible inbred mice strain. J Pathol 1986; 150: 257-65.
30. Ryley JF, McGregor S, Lister SC et al. Kidney function in experimental systemic candidosis of mice. Mycoses 1988; 31: 203-7.
31. Cheron M, Petit C, Bolard J et al. Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774. J Antimicrob Chemother 2003; 52: 904-10.
32. Bekersky I, Boswell GW, Hiles R et al. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats. Pharm Res 2000; 17: 1494-502.
33. Boswell GW, Bekersky I, Buell D et al. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother 1998; 42 263-8.
34. Echevarría I, Barturen C, Renedo MJ et al. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin b-deoxycholate in rats. Antimicrob Agents Chemother 2000; 44 898-904.
35. Ostrosky-Zeichner L, Marr KA, Rex JH et al. Amphotericin B: Time for a new 'gold standard. Clin Infect Dis 2003; 37: 415-25.
36. Kwong EH, Ramaswamy M, Bauer EA et al. Heat treatment of amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal, toxicity following administration of a single intravenous dose to rabbits. Antimicrob Agents Chemother 2001; 45: 2060-3.
37. García-Fontgivelt JF, Mayayo Arial E. Prevalence of fungal infections detected from biopsies and autopsies in the past 11 years at the University Hospital Joan XXIII in Tarragona, Spain. Rev Iberpam Micol 2006; 23: 201-8.
38. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006; 27S: S12-6.
39. Martino A. Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): A review of the literature. Curr Med Res Opin 2004; 20: 485-504.